IMMX 241220 7.50P (IMMX241220P7500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

IMMX241220P7500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 25 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
GlobeNewswireNov 25 09:32 ET
Immix Biopharma | 10-Q: Q3 2024 Earnings Report
SECNov 12 16:42 ET · Announcements
Immix Biopharma's Promising Therapeutic Candidate NXC-201 Fuels Buy Rating Amidst Strong Clinical and Financial Outlook
TipRanksOct 3 06:16 ET · Ratings
Express News | Immix Biopharma Inc: Now Dosing at Dose Expansion Level of 450 Mln Nxc-201 Car+T Cells
ReutersOct 2 09:33 ET
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
GlobeNewswireOct 2 09:32 ET
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
GlobeNewswireSep 19 09:31 ET

Comments

Trytosaveabit

20 hours ago

Update

$Immix Biopharma (IMMX.US)$ Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
GlobeNewswire·
75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy
Data will be presented on Monday, December 9, 2024 at 4:00 PM PT

Stock_Drift

20 hours ago

$Immix Biopharma (IMMX.US)$

Stock_Drift

Oct 2 10:07

$Immix Biopharma (IMMX.US)$

Stock_Drift

Sep 19 09:57

$Immix Biopharma (IMMX.US)$

Jaguar8

Aug 28 08:32

NEWS

$Immix Biopharma (IMMX.US)$
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Immix Biopharma (NASDAQ: IMMX) has expanded its U.S. clinical trial sites for the NEXICART-2 study, evaluating CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients. New sites include Cleveland Clinic, UC Davis, and Sutter Health, joining lead site Memorial Sloan Kettering Cancer Center. This expansion aims to increase patient access and enrollment opportunit...